Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 39 min ago
PreprintCC BYMedrxiv : the Preprint Server For Health Sciences

Autoantibodies neutralizing type I interferons in patients with life-threatening COVID-19 pneumonia: a meta-analysis from 2020–2026

Abstract

Autoantibodies neutralizing type I IFNs (AAN–IFN-I) have been found in significant proportions of cases of severe, critical, and fatal COVID-19 pneumonia. We performed a systematic review of 54 studies reporting auto-Abs against type I IFNs and a meta-analysis of 20 studies reporting auto- Abs neutralizing type I IFNs published between 2020 and 2026. The meta-analysis included data for 11,380 SARS-CoV-2-infected individuals from Europe, North America, South America, Asia, the Middle East, North Africa and international multicenter cohorts, including 7,814 with severe or critical disease (69%). The pooled prevalence of AAN–IFN-I was estimated at 7.9% (95% CI, 6.0–10.4). Disease severity was strongly associated with AAN–IFN-I prevalence (OR, 11.7; 95% CI, 7.6–17.9; P =5×10⁻²⁹). The pooled prevalence of AAN-IFN-I reached 11.4% (95% CI, 10.2– 12.7%) in patients with severe or critical COVID-19 and 15.3% (95% CI, 12.1–19.2%) in those who died. The prevalence of AAN–IFN-I increased with age in patients with severe, critical, or fatal COVID-19. AAN-IFN-I probably accounted for about 1.1 million of the 7.1 million deaths from COVID-19. AAN-IFN-I are strong, common, global determinants of life-threatening COVID-19 pneumonia.

Related

  1. Auto-antibodies neutralizing type I interferons in ~10% of Moroccan patients with life-threatening COVID-19
    Halima Kholaiq, Adrian Gervais, Paul Bastard +23
    Frontiers in ImmunologyPeer-reviewedCC BYFull text1 citedInfectious diseaseHAL
  2. Autoantibodies Against Type I Interferons and Death from H7N7 Avian Flu
    Qian Zhang, Ron A. M. Fouchier, Marcela Moncada-Velez +10
    The New England journal of medicinePeer-reviewedCC BY 4.0Full textEpidemiology & public healthPMC
  3. High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies
    Adrian Gervais, Astrid Marchal, Alexis Maillard +67
    Proceedings of the National Academy of Sciences of the United States of AmericaPeer-reviewedCC BYFull textGeneral biologyEpidemiology & public healthHAL
  4. Type I IFN autoantibodies in three of seven Europeans with life-threatening Usutu virus infection.
    Adrian Gervais, Paul Bastard, Lucy Bizien +26
    Journal of human immunityPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCPMCHAL
  5. Treating More Than One Tibial Arteries in Patients with Chronic Limb Threatening Ischaemia is Associated with Fewer Major Re-interventions*
    Matthew T. Menard, Jeffrey J. Siracuse, Kenneth Rosenfield +7
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular SurgeryPeer-reviewedLicence not statedFull text1 citedSurgery & anaesthesiaPMC
BibTeX
@misc{feredj2026autoantibodies,
  title = {{Autoantibodies neutralizing type I interferons in patients with life-threatening COVID-19 pneumonia: a meta-analysis from 2020–2026}},
  author = {Elsa Feredj and Qian Zhang and Paul Bastard and Jean-Laurent Casanova and Aurélie Cobat},
  howpublished = {Medrxiv : the Preprint Server For Health Sciences},
  year = {2026},
  month = aug,
  doi = {10.64898/2026.08.06.26359907},
  url = {https://hal.science/hal-05863798v1},
  note = {CC BY},
}
RIS
TY  - UNPB
TI  - Autoantibodies neutralizing type I interferons in patients with life-threatening COVID-19 pneumonia: a meta-analysis from 2020–2026
AU  - Elsa Feredj
AU  - Qian Zhang
AU  - Paul Bastard
AU  - Jean-Laurent Casanova
AU  - Aurélie Cobat
PY  - 2026
DA  - 2026/08/10
PB  - Medrxiv : the Preprint Server For Health Sciences
DO  - 10.64898/2026.08.06.26359907
UR  - https://hal.science/hal-05863798v1
AB  - Autoantibodies neutralizing type I IFNs (AAN–IFN-I) have been found in significant proportions of cases of severe, critical, and fatal COVID-19 pneumonia. We performed a systematic review of 54 studies reporting auto-Abs against type I IFNs and a meta-analysis of 20 studies reporting auto- Abs neutralizing type I IFNs published between 2020 and 2026. The meta-analysis included data for 11,380 SARS-CoV-2-infected individuals from Europe, North America, South America, Asia, the Middle East, North Africa and international multicenter cohorts, including 7,814 with severe or critical disease (69%). The pooled prevalence of AAN–IFN-I was estimated at 7.9% (95% CI, 6.0–10.4). Disease severity was strongly associated with AAN–IFN-I prevalence (OR, 11.7; 95% CI, 7.6–17.9; P =5×10⁻²⁹). The pooled prevalence of AAN-IFN-I reached 11.4% (95% CI, 10.2– 12.7%) in patients with severe or critical COVID-19 and 15.3% (95% CI, 12.1–19.2%) in those who died. The prevalence of AAN–IFN-I increased with age in patients with severe, critical, or fatal COVID-19. AAN-IFN-I probably accounted for about 1.1 million of the 7.1 million deaths from COVID-19. AAN-IFN-I are strong, common, global determinants of life-threatening COVID-19 pneumonia.
ER  -